health
In-vivo BCMA CAR-T follow-up finds one 15-month remission
A phase 1 follow-up of four patients with relapsed or refractory multiple myeloma found that one maintained a stringent complete response for 15 months. The other three progressed within five months, and median progression-free survival was 4.0 months.